1. Home
  2. RFL vs XGN Comparison

RFL vs XGN Comparison

Compare RFL & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RFL
  • XGN
  • Stock Information
  • Founded
  • RFL 2017
  • XGN 2002
  • Country
  • RFL United States
  • XGN United States
  • Employees
  • RFL N/A
  • XGN N/A
  • Industry
  • RFL Real Estate
  • XGN Medical Specialities
  • Sector
  • RFL Finance
  • XGN Health Care
  • Exchange
  • RFL Nasdaq
  • XGN Nasdaq
  • Market Cap
  • RFL 55.3M
  • XGN 72.3M
  • IPO Year
  • RFL N/A
  • XGN 2019
  • Fundamental
  • Price
  • RFL $1.92
  • XGN $5.15
  • Analyst Decision
  • RFL
  • XGN Buy
  • Analyst Count
  • RFL 0
  • XGN 1
  • Target Price
  • RFL N/A
  • XGN $7.00
  • AVG Volume (30 Days)
  • RFL 30.6K
  • XGN 164.8K
  • Earning Date
  • RFL 12-27-2024
  • XGN 11-12-2024
  • Dividend Yield
  • RFL N/A
  • XGN N/A
  • EPS Growth
  • RFL N/A
  • XGN N/A
  • EPS
  • RFL N/A
  • XGN N/A
  • Revenue
  • RFL $697,000.00
  • XGN $55,751,000.00
  • Revenue This Year
  • RFL N/A
  • XGN $6.74
  • Revenue Next Year
  • RFL N/A
  • XGN $17.32
  • P/E Ratio
  • RFL N/A
  • XGN N/A
  • Revenue Growth
  • RFL 151.62
  • XGN 8.00
  • 52 Week Low
  • RFL $1.29
  • XGN $1.30
  • 52 Week High
  • RFL $2.50
  • XGN $6.22
  • Technical
  • Relative Strength Index (RSI)
  • RFL 53.58
  • XGN 58.53
  • Support Level
  • RFL $1.71
  • XGN $4.71
  • Resistance Level
  • RFL $1.92
  • XGN $6.22
  • Average True Range (ATR)
  • RFL 0.10
  • XGN 0.55
  • MACD
  • RFL -0.00
  • XGN -0.02
  • Stochastic Oscillator
  • RFL 84.00
  • XGN 46.23

About RFL Rafael Holdings Inc. Class B

Rafael Holdings Inc is a holding company with interests in clinical and early-stage pharmaceutical companies. Its primary focus is to expand its investment portfolio through opportunistic investments including therapeutics, which address high unmet medical needs. Through the companies it has invested in, the company is focused on; developing Trappsol Cyclo its clinical program, developing instruments to advance minimally invasive surgeries, preclinical cancer metabolism research operations, and developing pharmaceutical-grade technology Unlokt for third-party cannabis manufacturers. It also holds and manages commercial real estate assets in Jerusalem, Israel. The company's reportable segments are; Infusion Technology, which derives maximum revenue, Healthcare, and Real Estate.

About XGN Exagen Inc.

Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.

Share on Social Networks: